Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Aventis Allegra Once-Daily New Prescription Market Share Reaches 13%

  • News

Executive Summary

Aventis' once-daily Allegra (fexofenadine) represents approximately half of the antihistamine's total new prescription market share, Pharmaceuticals CEO Richard Markham said during an analyst meeting in London March 2.

You may also be interested in...



Claritin Supply Sufficient For Spring, Schering Says; FDA Lists GMP Problems

Schering-Plough will have a sufficient supply of Claritin for the spring allergy season, the company maintains.

Schering-Plough Clarinex NDA Approval Awaits Resolution Of GMP Problems

Schering-Plough's Clarinex (desloratadine) NDA will not be approved until the company answers FDA concerns regarding Good Manufacturing Practices compliance at a wide range of Schering operations.

Schering Desloratadine Launch Ads In U.K. Include Decongestant Claim

Schering-Plough's launch campaign for desloratadine in the U.K. includes a claim that the antihistamine has decongestant properties.

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS037414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By